ALX Oncology

ALX Oncology

  • Founded: 2015
  • Location: South SF, CA
  • Employee range: 11 - 50
  • Clinical stage: Clin2 (fast track)
  • Therapy area: Head & neck cancer (partner: Merck)
  • Drug types: ONC
  • Lead product: Evorpacept
  • Product link:
  • Funding: $185.7M IPO Jul 2020; $105M C Feb 2020; $36M A Mar 2015

job board

Short description:


Drug notes:

Also different combo Clin2 (fast track) head & neck cancer (partner: MercK), Clin2 (fast track) gastric cancer (partner: Lilly), Clin1 urothelial cancer; 2 trials Clin1 breast cancer (one partnered: Zymeworks), Clin0 multiple myeloma; ALTA-002 Clin0 oncology

Long description:

ALX Oncology is developing immunotherapies for cancer treatment. CD47 is a cell surface protein expressed on cancer cells that signals to evade detection by the immune system. ALX’s approach revolves around inhibiting CD47 and the “don’t eat me” signal, known as checkpoint inhibition, to further stimulate the immune response against the cancer. The inhibitors are designed by ALX to have high affinity for CD47 and to avoid the limitations caused by hematologic toxicities seen in other immunotherapies. ALX believes their lead product candidate, evorpacept (ALX148), has a wide therapeutic window and can be combined with anti-cancer agents. Their current programs are focused on targeting CD47 across various oncology indications.


© 2023 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy